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Influenza A virus (IAV) is a significant human pathogen causing annual epidemics and periodic pandemics. CD8
+ cytotoxic T lymphocyte (CTL)-mediated immunity contributes to the clearance of virus-infected cells, and CTL immunity targeting the conserved internal proteins of IAVs is a key protection mechanism when neutralizing antibodies are absent during heterosubtypic IAV infection. However, CTL infiltration into the airways, its cytotoxicity, and the effects of produced proinflammatory cytokines can cause severe lung tissue injury, thereby contributing to immunopathology. Studies have discovered complicated and exquisite stimulatory and inhibitory mechanisms that regulate CTL magnitude and effector activities during IAV infection. Here, we review the state of knowledge on the roles of IAV-specific CTLs in immune protection and immunopathology during IAV infection in animal models, highlighting the key findings of various requirements and constraints regulating the balance of immune protection and pathology involved in CTL immunity. We also discuss the evidence of cross-reactive CTL immunity as a positive correlate of cross-subtype protection during secondary IAV infection in both animal and human studies. We argue that the effects of CTL immunity on protection and immunopathology depend on multiple layers of host and viral factors, including complex host mechanisms to regulate CTL magnitude and effector activity, the pathogenic nature of the IAV, the innate response milieu, and the host historical immune context of influenza infection. Future efforts are needed to further understand these key host and viral factors, especially to differentiate those that constrain optimally effective CTL antiviral immunity from those necessary to restrain CTL-mediated non-specific immunopathology in the various contexts of IAV infection, in order to develop better vaccination and therapeutic strategies for modifying protective CTL immunity.
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+ T cells, influenza, human, immune regulation, immunopathology, vaccination iNTRODUCTiON Influenza A virus (IAV) causes acute respiratory tract infection and is a significant human pathogen causing annual epidemics and periodic pandemics (1) . Annual influenza epidemics are caused by circulating "seasonal" influenza viruses, which currently include H1N1 and H3N2 subtype IAVs and influenza B viruses. The RNA genome of IAV has high mutation rates due to the high error rate of its RNA polymerase, allowing the viruses to quickly evolve under selection pressures to develop antigenically drifted strains. Occasional influenza pandemics are caused by the introduction of novel antigenically shifted strains to human populations. These strains, including 2009 pandemic H1N1 IAV, often result from the reassortment of different zoonotic IAVs (2) . Reassortment also can generate antigenically distinct new subtypes that pose a pandemic threat to the human population, such as the recent outbreak of human infections of zoonotic H7N9 IAV in China (3) . Due to their ability to constantly generate new strains through mutation and reassortment, IAVs pose continuing threats to human populations. Upon encountering IAVs, the complex host immune system senses the invasion and then mounts innate and adaptive immune responses intended to clear the virus. Multiple arms of host immunity are used for protection against influenza infection. The innate responses initiate inflammation, limit virus replication, and provide signals to activate adaptive immunity (4) . The ultimate control of virus replication and clearance of virus-infected cells rely on the virus-specific adaptive immune responses, including antibodies and CD4
+ and CD8 + T cells (5) . IAV-specific antibodies bind and neutralize viral proteins (neutralizing antibodies) or mediate other virus clearance activities (non-neutralizing antibodies) in cooperation with immune cells, including CD8
+ T cells and lung-resident phagocytes (6) (7) (8) (9) (10) . CD4
+ T cells help B cells for antibody production and CD8
+ T cells for activation and proliferation. It has been long acknowledged that CD8 + cytotoxic T lymphocyte (CTL)-mediated immunity contributes to virus clearance through cytolysis of the virus-infected target cells and production of cytokines that further enhance antiviral inflammation (11) . However, there is accumulating evidence that the IAV-specific CD8
+ T cells and their effector mediators also contribute to immunopathology during IAV infection. A variety of mechanisms have been uncovered to regulate the magnitude and effector activities of IAV-specific CTL responses for effective virus clearance while limiting inflammation during influenza infection.
Here, we first review the historical advances in understanding protective and immunopathogenic roles of IAV-specific CTL responses using either IAV infection or non-viral infection models. Next, we focus on the current state of knowledge for how various regulatory mechanisms control immune protection and pathology by CTL responses during influenza infection. This is followed by a discussion of clinical findings about the role of CTL responses in human IAV infections, highlighting the evidence that emerged after the 2009 H1N1 pandemic and recent outbreaks of human infection by H7N9 IAVs. Finally, we summarize our current understanding of the multiple layers of host and viral factors mediating the outcome of antiviral CTL responses and suggest future key research directions.
iAv iNFeCTiON iNDUCeS ANTiviRAL CD8 + T-CeLL ReSPONSeS
The mammalian airways have very large mucosal surfaces for gas exchange. IAV infection begins with virus invasion and replication in the upper airway epithelium, and from there, it can spread further into the lower airways and lung, causing severe infection. Meanwhile, the lung epithelial and endothelial cells and other airway resident innate cells, including several dendritic cell (DC) subsets, alveolar macrophages, and innate lymphoid cells, sense the viruses and initiate innate inflammation, acting as the first line of defense (4) . Innate and epithelial cells use specific pattern recognition receptors (PRRs) to recognize various viral products containing pathogen-associated molecular patterns (PAMPs), including endosome-bound TLR3 (dsRNA), TLR7/8 (ssRNA), cytosolic RIG-I (ssRNA), and NLRP3 (viral ssRNA) (12) . Innate sensing of viruses initiates production and/or release of various inflammatory cytokines, including type I interferon (IFN), IL-1β, IL-6, and TNF-α. These cytokines induce multiple mechanisms in the infected cells to limit virus replication and also stimulate DC activation for effective antigen acquisition and presentation to initiate IAV-specific adaptive responses. At least three subsets of lung-resident DCs have been found to play a role in responding to IAV infection in mice (13, 14) . Lung plasmacytoid DCs (pDCs) are classic potent producers of type I IFN after detecting virus (15) but were initially thought to be dispensable for antiviral T-cell immunity (16) . However, recent studies found that pDCs also migrate into lung-draining lymph nodes (LNs) to play a different role in certain IAV infection contexts (17, 18) that will be discussed later in this review. Two subsets of lung DCs, CD103
+ and CD11b + DCs, are migratory DCs (19, 20) that bridge innate and adaptive immunity during influenza infection. After being activated by virus infection and innate cytokines, they migrate out of the inflamed lung into the lung-draining LNs in a CCR7-mediated way (21) , carrying the acquired viral antigen; in the LNs, these migratory DCs either directly present antigens to naive T cells or transfer the antigen to other specific LN DC populations for further presentation to naive T cells (19) . Naive T cells in the LNs recognize the presented IAV-specific antigens using their T-cell receptors (TCRs) and receive various costimulation signals from the activated DCs, sequentially undergoing clonal selection, expansion, activation, and differentiation into IAV antigen-specific effector CD4
+ and CD8 + T cells. Studies have shown that, following IAV infection, accelerated migration of DCs carrying antigens from the infected lung to LNs occurs only during the early phase of infection (the first 36 h after infection) (22, 23) , and activation of the naive T cells in the LNs then occurs in an ordered, sequential fashion, in accordance with the tempo of the DC migration (23) .
Influenza A virus infection drives CD4 + T-cell differentiation mainly into Th1 effector T cells. These "helper" cells provide help to B cells and CD8 + T cells in different ways via costimulatory signals and cytokines. Notably, CD4
+ T-cell help is not essential for the primary effector CD8 + T-cell responses (24) , although it is important for the generation of the optimal magnitude of memory CD8
+ T-cell responses after IAV infection (25) . Effector CD8 + T cells then migrate from the LNs into the infected and inflamed lung where the survival and proliferation of the CTLs are further shaped by interactions with various non-migratory DC populations in lung (26) (27) (28) . IAV-specific effector CD8 + T cells are cytotoxic cells equipped to specifically recognize and kill the virus-infected cells and produce various cytokines.
Following IAV clearance, the generated virus-specific B cells and CD4
+ and CD8 + T cells undergo a rapid contraction phase with only a small proportion surviving and differentiating into memory cells, which form the memory pool necessary to protect against future infections with the same or similar viruses. During this process, chemokine receptors CCR5 and CXCR3 are important in regulating the virus-specific CTL contraction and memory generation within the infected lung (29, 30) . Studies have shown that residual IAV antigen depots in lung-draining LNs can persist for weeks after virus clearance; the prolonged presentation of the residual antigen does not prime new naive CD8 + T cells (31) but helps to maintain the large number of the memory CD8
+ T cells in the draining LNs or in the lung airways possibly by regulating circulation patterns and activation states of the local memory CD8
+ T cells (32) (33) (34) . However, in contrast to the lung populations, this antigen is not required for maintenance and circulation of the peripheral memory CD8 + T cells (35) . Recently, three major subsets of memory T cells are recognized based on their anatomical location, migration patterns, and additional phenotypic and effector markers: central memory T cells (Tcm), effector memory T cells (Tem), and tissue resident memory T cells (Trm). The biology of these different subsets is outside the scope of the current review.
It is worth noting that during the differentiation of naive CD8 + T cells into effector CTLs and then into distinct memory subsets, the cells undergo massive transcriptional programing that regulates their effector or memory potential (36) . IRF4 (37, 38) and Blimp1 (39) have been found as important transcription factors that regulate CTL clonal expansion, effector differentiation, and/ or effector activity during IAV infection.
In the following review, we discuss how the activation, proliferation, survival, migration, localization, and effector activity of IAV-specific CD8 + T cells are tightly regulated by antigen load, multiple cytokines, and costimulatory and/or coinhibitory signals provided by various cells in the LNs and in the infected lung. Appropriate control of the magnitude and effector activity of IAV-specific CD8 + cells is required both for an effective antigen removal and for limiting the potential immunopathology.
iAv-SPeCiFiC CD8
+ T CeLLS ARe CYTOTOXiC AND CYTOKiNe/ CHeMOKiNe-PRODUCiNG CeLLS Influenza A virus-specific CD8 + CTLs play a vital role in eliminating IAV-infected host cells in the lung through their two well-defined effector activities: antigen-specific cytotoxicity and cytokine/chemokine production. The CTLs target only virus-infected host cells, using their TCRs to recognize specific viral peptides (p) in complex with host major histocompatibility complex (MHC) molecules (pMHC) on the cell surface. TCR recognition and engagement of pMHC is a prerequisite for subsequent CTL cytotoxicity and cytokine production. CTL cytotoxicity is mediated in three known ways: perforin/ granzyme-mediated cytolysis, apoptosis mediated by FasL/Fas, and TRAIL/TRAIL-DR signaling (40) (41) (42) (43) . CTLs contain a poreforming protein (perforin) and cytotoxic granules comprising proapoptotic proteases called granzymes. Perforin complexes form pores between the CTL and target cell, and the granules then release granzymes into the target cells through these pores, with granzyme B one of the most abundant (40) . CTLs also use two membrane-bound TNF family ligands, FasL and TRAIL, for targeted cell killing. Engagement of these molecules with their cognate receptors (Fas and TRAIL-DR) on infected cells initiates an apoptotic signaling cascade (41) (42) (43) .
Influenza A virus-specific CD8 + CTLs are also equipped to produce a range of cytokines and chemokines. Classically, IFN-γ and TNF-α are the most prominent effector cytokines produced by CTLs, and cells producing them are often referred to as classical "Tc1" cells. IFN-γ is a potent antiviral cytokine. It can enhance the cytotoxicity of other immune cells, promote further activation of DCs, and help B cells to promote antibody isotype switching (44) . TNF-α is primarily a proinflammatory cytokine, induces non-specific death of infected cells, and regulates the function of other immune cells through TNFRs (45) . CTLs are not the main source of IL-2, but a small proportion of CTLs can produce IL-2 after receiving certain costimulatory signals, which in return may provide proliferation and survival signals to themselves and other CTLs (46) . CTLs producing IFN-γ, TNF-α, and IL-2 are considered more potent than those producing only one or two cytokines (47) . Different subsets of IAV antigen-specific CTLs differ in their ability to produce combinations of the three cytokines (48) .
IL-10 is usually produced by regulatory CD4 + T cells (Treg) and/or helper CD4 + T cells. It is commonly recognized as an immune regulatory/anti-inflammatory cytokine that serves as a brake on ongoing inflammation. IL-10 was found to be produced in large quantities in IAV-infected lungs, and surprisingly, the effector CD8 + T cells that simultaneously produced IFN-γ contributed a large fraction of IL-10 (49). Blocking the action of IL-10 during IAV infection resulted in enhanced pulmonary inflammation and lethal injury (49) . Thus, CD8
+ T cells produce both anti-inflammatory IL-10 and antiviral IFN-γ to fine-tune the CTL activity to an effective but restrained level.
Recently, studies found small subsets of CD8 + effector T cells in the IAV-infected lung that could produce non-classical CTL cytokines (50-53): "Tc2" cells producing IL-4, IL-5, and IFN-γ and "Tc17" cells producing IL-17 and IFN-γ. In vitro polarized Tc2 and Tc17 cells are as cytotoxic as Tc1 cells, and the adoptive transfer of Tc2 or Tc17 cells into infected mice provided different levels of survival protection after otherwise lethal IAV infection (50, 52, 53) . Relative to Tc1 cells, Tc2 and Tc17 cells account for a very small proportion of effector CD8 + T cells in vivo, and the extent of their effector activity during IAV infection in vivo needs to be further defined.
The two CTL effector activities (cytotoxicity and cytokine production) are precisely regulated in the infected lung by a variety of factors, including their anatomic localization and their interactions with different antigen-presenting cells with diverse pMHC density and costimulatory signals, to achieve effective target cell killing while limiting non-specific inflammation (Figure 1) . These mechanisms will be discussed in detail below.
+ T CeLLS ARe CRUCiAL FOR viRUS CLeARANCe AND PROviDe PROTeCTiON DURiNG iAv iNFeCTiON
The role of CTLs in clearing IAV has been demonstrated in multiple studies using adoptive transfer of IAV-specific CTLs into naive recipient mice ( Table 1) . In these studies, after the adoptive transfers, lung virus titers and/or the time to virus clearance were reduced, leading to accelerated recovery from non-lethal infection or survival of otherwise lethal infection (54) (55) (56) . The contribution of CTLs to protective anti-IAV immunity is further corroborated by studies using β2-M-deficient mice, which are defective in MHCI complex assembly and antigen presentation and thus fail to produce functional CD8 + T cells (57) . The β2-Mdeficient mice showed a significantly delayed pulmonary virus clearance after non-lethal IAV infection and a significantly higher mortality rate after a lethal IAV infection than the control β2-M heterozygous mice (57) , showing that CD8 + T-cell immunity is important in protection against IAV infection. However, both the β2-M-deficient mice and mice depleted of CD8 + T cells were able to eventually clear the virus and recover from non-lethal IAV infection (58) , suggesting that the CTL response is not the sole effector of antiviral immunity during IAV infection. IAV-specific immunity consists of multiple immune mechanisms, including CTLs, antibodies, and CD4 + T-cell responses, which promote IAV clearance and host protection.
Both CTL effector activities (cytotoxicity and cytokine production) can contribute to protective immunity, but antigenspecific target cell destruction by CTL cytotoxicity is believed to be the primary CTL activity used for IAV clearance (11) . Earlier studies showed that either perforin/granzyme-or FasL/Fas signaling-mediated apoptosis provided sufficient CTL cytotoxicity for efficient virus clearance (41) . Later, TRAIL/TRAIL-DR signaling was found to contribute to CTL cytotoxicity and virus clearance (42, 43) . In a non-viral infection model, in the absence of perforin, the antigen-bearing alveolar epithelial cells are not sensitive to FasL/Fas-induced cell death mediated by transferred antigen-specific CTLs, suggesting that CTLs may use different The two effector activities of IAV-specific CTLs allow effective specific killing of virus-infected cells but can also cause nonspecific, tissue-destructive inflammation. In an earlier study, IAV infection of athymic nude mice, which cannot generate functional T cells, led to a longer survival and a slower progression of lung pathology than infection of wild-type mice, but the nude mice had a lower eventual survival rate, persistent lung injury, and higher lung virus titers (59) . This study provided a first glimpse into the double-edged effects of antiviral T-cell immunity: while it provides necessary protective immunity, it does so at the cost of immunopathology. Since that study, immunopathology caused by IAV-specific CTLs has been further elucidated ( Table 2) .
One study used a non-viral infection model with CD8 + T CTLs specific for an IAV hemagglutinin (HA) antigen adoptively transferred into mice whose alveolar epithelial cells constitutively expressed the HA antigen. The CTL-mediated immune response is initiated when the transferred CTLs recognize the HA antigen (60) . In this model, the contribution of the IAV-specific CTLs to lung immunopathology can be isolated from inflammation caused by virus replication, allowing detailed dissection of lung immunopathology caused by CTL cytotoxicity, TNF-α/IFN-γ release, and their subsequent effects on alveolar epithelial cells ( Table 2 ). This non-viral infection model was able to cause lethal lung injury. The recipient mice showed progressive weight loss, interstitial pneumonitis, compromised lung structure and function, and increased inflammatory cytokine levels in the lung, demonstrating that IAV-specific CTLs can cause immunopathology (60, 61) . Subsequent studies using this model revealed that the transferred CTLs were present only transiently (24-48 h) in the lung, and the targeted antigen-specific alveolar cells were stimulated by interaction with the CTLs to produce MCP-1 and other inflammatory mediators before they underwent apoptosis, causing lung inflammation (62) . The soluble TNF-α released by the CTLs induced further inflammatory cytokine production (65) (66) (67) 69) and non-specific apoptosis of bystander alveolar epithelial cells (63) , contributing to both lung injury and inflammation. Additionally, IFN-γ production by the CTLs and subsequent IFN-γ signaling contributed to lung immunopathology (64) .
By isolating IAV-specific CTL responses, the non-viral infection model provided valuable insights into the CTLs' contributions to lung immunopathology. It is also important to note that the sustained presence of IAV antigen in this model is not commonly found in the IAV infection model where the virus is eventually cleared; thus, the immunopathogenic effects of IAV-specific CTL responses were likely excessively amplified in this model and did not capture the protective effects that these cells provide in a natural infection. For example, a study using mice that express a TNF-α inhibitor in their alveolar epithelium demonstrates that TNF-α produced by the CTLs is a doubleedged sword: it indeed facilitates virus clearance but at the same time contributes to severe lung immunopathology (68) . Thus, it is this delicate balance between immune protection and pathology mediated by CTLs that determines the overall outcome in the host.
BALANCiNG THe iMMUNe PROTeCTiON AND iMMUNe PATHOLOGY OF CD8

+
T CeLLS DURiNG iAv iNFeCTiON
After IAV infection, infiltration of the lung by IAV-specific CTLs and their subsequent effector activities are essential for virus clearance but also contribute substantially to lung immunopathology; therefore, IAV-specific CTL responses must be balanced to mount effective antiviral immunity but limit tissue immunopathology. Studies using mouse models have provided insights into the complex, exquisite, control, and regulation of the magnitude of IAV-specific CTLs and their effector activities. These regulatory mechanisms include various costimulatory/ inhibitory signals, cytokine/chemokine signals, and different cell-cell interactions, among others, to balance the protective ( Table 3 ) against pathological (Table 4) effects by IAV-specific CTLs (Figure 1) .
In addition to antigen stimulation, effective CD8 + T-cell responses are commonly believed to require secondary costimulatory signaling from DCs and/or proliferation signals from CD4 + helper T cells. However, during IAV infection, the primary IAV-specific CTL response is largely independent of CD4 + helper T cells (24) . Thus, various costimulatory signals from DCs and other innate immune cells are particularly important in generating effective IAV-specific CTL immunity. Studies using specific receptor-deficient mice and/or signaling blockade have shown that both CD80/CD28 and CD70/27 costimulatory signaling are pivotal for initial activation and expansion of IAV-specific naive CD8 + T cells in LNs (70, 83) , and CD70/27 is especially critical for accumulation of the CTLs in the infected lung by sustaining their survival (46, 84) . Other costimulatory signals, including 4-1BBL/4-1BB, CD40L/CD40, and OX40L/OX40, collectively contribute to generate the optimal CTL response magnitude at late stages of infection and/or the optimal size and responsiveness of the memory CTL pool (83, 85, 86) .
CD40L on the activated DC subsets provide important costimulatory signals in optimizing the magnitude of IAV-specific CTL responses in CD4 + T cell-independent immunity (71, 87) . One study used an adenovirus-produced recombinant CD40L fused with IAV NP antigen (rAD-SNP40L) to target CD40 during IAV infection; this treatment successfully enhanced NP-specific CTL and antibody responses, reduced lung virus titers, and protected the mice from otherwise lethal IAV infection (71) . Notably, type I IFN and IL-1 innate cytokines induced by IAV replication can activate DCs to increase the expression of these costimulatory molecules and thus promote IAV-specific CD8 + T-cell immunity (88, 89) .
Another costimulatory receptor, 4-1BB, is differentially expressed on IAV-specific CTLs in lungs after infection with a low-and a high-pathogenic IAV. The higher level of 4-1BB is required to mount a higher magnitude of IAV-specific CTL responses for effective clearance of the high pathogenic IAVs (77) . However, intranasal delivery of adenoviral-4-1BBL into the 4-1BBL-deficient mice after the high pathogenic IAV infection marginally improves survival at a low dose but exacerbates disease at a high dose; delivery of both doses of 4-1BBL-AdV into wild-type mice led to an increased mortality (77) . This finding demonstrates an example that inducible costimulatory molecules have to be balanced to develop antiviral CTL immunity to a level commensurate with the pathogenicity of the IAVs. Costimulatory signals can also result in exuberant T-cell inflammation that contributes to immunopathology. OX40 is a costimulatory receptor expressed only on activated T cells, and its interaction with OX40L on DCs imparts a survival signal to the T cells, preventing activation-induced cell death (90) . Blockage of OX40L/OX40 signaling during IAV infection by administration of an OX40 fusion protein significantly reduced the magnitude of both IAV-specific CTL and CD4 + T-cell responses (78) . However, unlike the effects of other costimulatory signals described above, reduction of T-cell responses by OX40L/OX40 blockade ameliorated disease symptoms without compromising effective virus clearance (78) . Clearly, OX40L/OX40 signaling during IAV infection is not necessary for virus clearance but contributes to immunopathology.
On the other hand, there are also various coinhibitory receptors on T cells, mediating inhibitory signals to activated T cells. Coinhibitory signaling serves to prevent tissue damage by limiting the response magnitude but also may constrain the effective immunity necessary for protective efficacy. For example, tissue-expressed Galectin-9 (Gal-9) binds to its receptor Tim-3 on T cells to limit the response magnitude. Gal-9 deficiency or blockade of Tim-3 signaling resulted in more robust virus-specific CTL and antibody responses to IAV infection, leading to a more rapid virus clearance and recovery (76) , suggesting that Gal-9/ Tim-3 signaling constrains effective antiviral immunity. NKG2A/ CD94, another inhibitory receptor originally described mainly on NK cells, was found to be expressed on IAV-specific CTLs during IAV infection. Deficiency of NKG2A or its ligand Qa-1b, or blockage of Qa-1b/NKG2A signaling, resulted in a greater pulmonary pathology accompanied by an enhanced TNF-α production by the IAV-specific CTL cells (80, 81) ; therefore, NKG2A-mediated negative signaling truly limits CTL immunity-mediated lung injury. Another inhibitory receptor, CD160, was also recently found on CD8 + T cells during influenza infection, and CD160-ligand/ CD160 signaling reduced the proliferation capacity and perforin expression of the CD8 + T cells (91) , although the role of this negative signaling in the outcome of the IAV infection is unclear.
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Frontiers in Immunology | www.frontiersin.org PD-1 is another inhibitory receptor found to be unregulated on IAV-specific CTLs after primary or secondary IAV infection, and its ligand PD-L1 was found to be expressed on lung epithelial cells and innate immune cells (74, 75, 79) . PD-L1/PD-1 signaling leads to severe functional impairment of CTLs. Inhibition of PD-L1/ PD-1 signaling during IAV infection by blocking either PD-1 or epithelial PD-L1 with antibodies in wild-type mice enhanced CTL function and subsequent virus clearance and ameliorated disease severity (74, 75) . However, in PD-1-deficient mice, CTL magnitude and function were improved after IAV infection, but recovery was delayed (79) , suggesting that PD-1-negative signaling is required to limit the adverse effects of the IAV-specific CTL responses. Clearly, this negative signaling is necessary to balance CTLs' role in virus control, speed of recovery, and immunopathology. Interestingly, another study found that only infection with highly pathogenic but not with low pathogenic IAV induced a greater PD-1 expression on the IAV-specific CTLs (75), demonstrating that the optimal magnitude of antiviral CTL immunity can be dampened as a consequence of the high pathogenicity of a particular IAV.
Plasmacytoid DCs are also found to negatively regulate the magnitude of CTL responses in LNs after lethal infection with a high dose of IAV or with a highly pathogenic H5N1 IAV but not after sublethal infection (17, 18) . After the lethal infections, pDCs accumulating in the LNs showed a high expression of FasL, driving the elimination of Fas + CD8 + cells. The dampened IAV-specific CTL responses enhanced the lethality of the infections, providing another example of how the optimal magnitude of antiviral CTL responses can be compromised in infections with IAVs of high pathogenicity, consistent with the clinical findings of lymphopenia in patients infected with highly pathogenic H5N1 IAVs (92) .
Various soluble cytokines induced during IAV infection also play an important role in the trafficking, survival, and effector activity of CD8 + effector T cells required for optimal antiviral CTL responses. For example, IL-15 is chemotactic, responsible for the migration of IAV-specific CTLs to the infected lung (93) and also contributes to the survival of the CTLs in the infected lung (27, 93) . Both IL-7 (72) and IL-18 (73) are necessary for the development of a robust IAV-specific CTL response required for efficient virus clearance. IL-12 was also shown to be important for CTL cytotoxicity in vitro (94) .
Two signaling molecules, TNF-α and TRAIL, used in the effector mechanisms of CTLs, can also constrain the magnitude of IAV-specific CTL responses to prevent the excessive damage. TRAIL deficiency (82) and TNF-α deficiency (66) increased the number of IAV-specific CTLs accompanied with decreased apoptosis and increased proliferation but increased host morbidity and mortality after IAV infection. Thus, both TRAIL/TRAIL-DR signaling and TNF-α/TNFR1 signaling have a dual role during IAV infection depending on the cell type in which the receptors are expressed: they can kill IAV-infected cells for immune protection and also negatively regulate the magnitude of the CTL response to reduce the likelihood of immunopathology.
Various types of innate and adaptive immune cells, including IAV-specific CTLs, infiltrate the IAV-infected lung. These infiltrating cells, the lung-resident cells, and the cytokines that they produce compose the local inflammation milieu, which can further shape the antiviral CTL response. For example, maintaining an optimal magnitude of protective IAV-specific CTL responses requires interactions with multiple non-migratory DC subsets in the infected lung for essential survival and proliferation signals (26) (27) (28) . An inflammatory monocyte population (sometimes referred to as TipDCs) is recruited from bone marrow to the infected lung by CCL2/CCR2-mediated chemoattraction. TipDCs and the TNF-α that they produce promote IAV-specific CTL expansion and survival in the lung, which are required for optimal protection (95) . The IAV-infected lung is also characterized by a large neutrophil infiltration. Migrating neutrophils leaves behind long-lasting CXCL12-enriched trails and routes into the infected lung to facilitate efficient CD8 + T-cell migration and localization to the infection site, which is required for optimal CTL infiltration and effective virus clearance (96) . In the lung interstitium, neutrophils also serve as antigen-presenting cells that promote IFN-γ production by CTLs (97) . NKT cells are recruited to the lung, where they themselves have a protective role against IAV infection (98) . Furthermore, NKT cells also promote the accumulation of CD103 + DCs in the LNs and promote the subsequent IAV-specific CD8 + T-cell response (99) . Finally, IAV antigen-specific Treg cells are found in both primary and secondary IAV infections, negatively regulate the proliferation of IAV-specific CTLs, and limit the pulmonary inflammation during secondary IAV infection (100) .
During IAV infection, not only is the magnitude of the antiviral CTL response regulated by multiple signals from various cells, but also the antiviral effector activities of the CTLs are dictated by the target cell type encountered and the costimulatory signals and antigen intensity the target cell carries. For example, CD45
+ inflammatory mononuclear cells in the lung interstitium, such as CD11c-high cells, which express costimulatory ligands (CD80/86), stimulate both CTL cytotoxicity and release of inflammatory cytokines, but CD45
− respiratory epithelial cells expressing few stimulatory ligands trigger only CTL cytotoxicity (14, 101) . Consistent with this finding, after adoptive transfer into IAV-infected mice, highly cytotoxic Tc1 cells were found to localize near the infected airway epithelium, but Tc2 cells localized within the clusters of other inflammatory cells distant from epithelium (50) , suggesting that different subsets of CD8 + T cells might interact with the subsets of innate cells resulting in diverse effector activities.
During the CTL and target cell interaction, CTL TCR recognition of its cognate pMHCI complex on the target cells determines the specificity of CTLs, while the strength of TCR/pMHCI recognition fine-tunes the extent of CTL effector activities (102) (103) (104) . The requirements of TCR occupancy and signal strength to activate CTL cytotoxicity are very low to minimal, allowing rapid and specific target cell killing, while the requirement for the induction of inflammatory cytokines is much higher, limiting the extent of non-specific inflammation induced by the cytokines (102-104) . Thus, the division of specialized roles among the different antigen-presenting cells and the two activation thresholds for the two CTL effector activities enable specific target cell killing while not necessarily causing excessive inflammation in the infected lung. In addition, from a temporal view of IAV replication and the antiviral CTL response, it is also reasonable to speculate that higher viral antigen load and stronger TCR signals on CTLs at the early phase of infection may promote terminal CTL effector of the population worldwide is infected annually with a seasonal IAV (105) . Thus, human IAV infections are almost invariably at least secondary, except in young children. Therefore, it is of great importance to understand heterosubtypic IAV immunity, which is generated by a given IAV subtype but offers some protection against challenge with another IAV subtype. In the face of a heterosubtypic IAV infection, the neutralizing antibodies generated by IAV-specific B cells can recognize only the specific IAV surface proteins from a previous infection, while IAV-specific CTLs target viral peptides that usually are derived from IAV internal proteins and are relatively conserved across different subtypes (106) . Thus, cross-reactive IAV-specific CTLs generated by previous IAV infection are an essential component of heterosubtypic immunity (107, 108) , as shown consistently in both animal and human studies. Animal studies ( Table 5 ) using a prime/challenge model with IAVs of different subtypes have shown that the cross-reactive CD8 + T cells generated by a first IAV infection are unable to prevent secondary IAV infection but clearly ameliorate morbidity and mortality, reduce the virus load, and accelerate recovery; this protection can even boost survival after an otherwise lethal challenge with H5N1 or H7N9 IAV (109) (110) (111) (112) (113) (114) (115) . These studies have consistently demonstrated that CD8
+ T cells mediate heterosubtypic immunity. One study found that the best predictor of protective efficacy against secondary infection was the overall size of the memory CTL pool generated by the priming infection, rather than conservation of known CD8
+ epitopes between viruses (114). The size of the memory CTL pool may serve as a proxy indicator of the robustness and quality of the primary immune response and may be associated with the activation status and quality of memory CTLs. Meanwhile, this finding also illustrates our incomplete understanding of the full measure of CD8 + epitope diversity and other heterologous immune mechanisms generated by initial priming, which warrants future studies.
Due to the many challenges posed by human studies, the role of CD8 + T cells in mediating heterosubtypic protection against illness caused by natural IAV infection is far from certain, but studies using human samples have provided some useful insights. A number of studies of human peripheral blood cells have demonstrated the existence of cross-reactive CD8 + T-cell immunity between distinct heterosubtypic IAVs, such as between seasonal IAVs and 2009 pandemic H1N1 IAV (116, 117) , between the 1918 pandemic H1N1 and 2009 pandemic H1N1 IAVs (118) , between seasonal IAVs and avian H5N1 IAVs (119) , and between seasonal IAVs and the novel H7N9 IAVs (115, 120, 121) . These studies consistently show that prior IAV infection in humans can generate a measure of cross-reactive, or "heterosubtypic, " CD8 + T-cell-mediated immunity against other serologically distinct IAVs, for potential immune recall responses upon another IAV infection.
A few studies in humans have demonstrated that the crossreactive IAV-specific CD8 + T-cell response is a positive correlate of cross-protective immunity against secondary IAV infection ( Table 6 ). An earlier human study using experimental H1N1 challenge showed that the extent of CTL cytotoxicity in the blood of subjects at 2 days after challenge was closely associated with less virus shedding, faster virus clearance, and less severe symptoms (122) , providing the first evidence that the preexisting cross-reactive CTL response is a correlate of clinically cross-protective immunity (day 2 was too early to generate CTL responses to the challenge IAV). The 2009 H1N1 pandemic and the recent emergence of human infections with H7N9 IAV in China have provided unique opportunities to study the natural heterosubtypic IAV infection and cross-protective response in the absence of the specific neutralizing antibodies. One study followed a cohort of healthy adults through the pandemic waves in the UK (123) , and another examined a cohort of hospitalized patients with severe H7N9 infection in China (124) . Both studies found that the magnitude of the cross-reactive CD8 + T-cell response was positively correlated with a favorable clinical outcome in the patients. Although these findings are consistent with those obtained in mice, it is noteworthy that human studies often involve complex and uncontrollable variables, including demographic, environmental, and genetic differences. As a consequence, extreme care must be taken in interpreting the results of human studies.
CONCLUDiNG ReMARKS
Due to their naturally high mutation rate and their ability to generate genetic reassortants, IAVs pose a continuing threat to human populations. In order to develop better therapeutic and vaccination strategies to appropriately modify CTL immunity for protection against IAV infection, it is a great need to better understand the regulation and balance of the immune protection and pathology involved in virus-specific CTL immunity during IAV infection. We argue that the counterbalance of these effects depends on multiple layers of host and viral factors, including complex host mechanisms that regulate CTL quantity, quality, and effector activities; the pathogenic profile of the IAV, especially its ability to induce different innate host response milieus in which CTL immunity is primed and regulated; and the historical immune context of influenza infection (e.g., primary, secondary, and postvaccination). We propose that future research efforts should refine our understanding of key host and viral parameters, their points of interaction, and the effects of these interactions under different contexts of influenza occurrence (primary, secondary, postvaccination challenge, or heterologous infection), especially to differentiate those that constrain optimally effective CTL antiviral immunity from those truly necessary to restrain CTL-mediated non-specific immunopathology. Further translational research efforts can then focus on developing preventive or therapeutic means to modulate these parameters and interactions to obtain the best clinical outcomes.
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